과제정보
This research was supported by a grant (22212MFDS254) from the Ministry of Food and Drug Safety and by the Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2017M3A9E4078017).
참고문헌
- Woo PC, Lau SK, Lam CS et al (2012) Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 86, 3995-4008 https://doi.org/10.1128/JVI.06540-11
- Zhu N, Zhang D, Wang W et al (2020) A novel Coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382, 727-733 https://doi.org/10.1056/NEJMoa2001017
- Dhama K, Khan S, Tiwari R et al (2020) Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev 33, e00028-20
- Ullrich S and Nitsche C (2020) The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 30, 127377
- Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H and Haddad Kashani H (2020) The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551, 1-9 https://doi.org/10.1016/j.virol.2020.08.011
- Tison GH, Avram R, Kuhar P et al (2020) Worldwide effect of COVID-19 on physical activity: a descriptive study. Ann Intern Med 173, 767-770 https://doi.org/10.7326/M20-2665
- Mallah SI, Ghorab OK, Al-Salmi S et al (2021) COVID-19: breaking down a global health crisis. Ann Clin Microbiol Antimicrob 20, 35
- Kim D, Lee JY, Yang JS, Kim JW, Kim VN and Chang H (2020) The architecture of SARS-CoV-2 transcriptome. Cell 181, 914-921 e910
- Ullrich S and Nitsche C (2022) SARS-CoV-2 papain-like protease: structure, function and inhibition. Chembiochem 23, e202200327
- Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565-574 https://doi.org/10.1016/S0140-6736(20)30251-8
- Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273 https://doi.org/10.1038/s41586-020-2012-7
- Stevens CS, Oguntuyo KY and Lee B (2021) Proteases and variants: context matters for SARS-CoV-2 entry assays. Curr Opin Virol 50, 49-58 https://doi.org/10.1016/j.coviro.2021.07.004
- Huff S, Kummetha IR, Tiwari SK et al (2022) Discovery and mechanism of SARS-CoV-2 main protease inhibitors. J Med Chem 65, 2866-2879 https://doi.org/10.1021/acs.jmedchem.1c00566
- Banerjee R, Perera L and Tillekeratne LMV (2021) Potential SARS-CoV-2 main protease inhibitors. Drug Discov Today 26, 804-816 https://doi.org/10.1016/j.drudis.2020.12.005
- Noske GD, Song Y, Fernandes RS et al (2023) An insolution snapshot of SARS-COV-2 main protease maturation process and inhibition. Nat Commun 14, 1545
- Jiang Z, Feng B, Zhang Y et al (2023) Discovery of novel non-peptidic and non-covalent small-molecule 3CL. Signal Transduct Target Ther 8, 209
- Ma C, Sacco MD, Hurst B et al (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res 30, 678-692 https://doi.org/10.1038/s41422-020-0356-z
- Magro P, Zanella I, Pescarolo M, Castelli F and Quiros-Roldan E (2021) Lopinavir/ritonavir: repurposing an old drug for HIV infection in COVID-19 treatment. Biomed J 44, 43-53 https://doi.org/10.1016/j.bj.2020.11.005
- Li C, Teng X, Qi Y et al (2016) Conformational flexibility of a short loop near the active site of the SARS-3CLpro is essential to maintain catalytic activity. Sci Rep 6, 20918
- Nashed NT, Aniana A, Ghirlando R, Chiliveri SC and Louis JM (2022) Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor. Commun Biol 5, 160
- Hsu WC, Chang HC, Chou CY, Tsai PJ, Lin PI and Chang GG (2005) Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J Biol Chem 280, 22741-22748 https://doi.org/10.1074/jbc.M502556200
- Miltner N, Kallo G, Csosz E et al (2023) Identification of SARS-CoV-2 Main protease (Mpro) cleavage sites using two-dimensional electrophoresis and in silico cleavage site prediction. Int J Mol Sci 24, 3236
- Vuong W, Khan MB, Fischer C et al (2020) Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 11, 1891
- Liu H, Iketani S, Zask A et al (2022) Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nat Commun 13, 1-16 https://doi.org/10.1038/s41467-022-29413-2
- Fu L, Ye F, Feng Y et al (2020) Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11, 4417
- Goyal B and Goyal D (2020) Targeting the dimerization of the main protease of coronaviruses: a potential broadspectrum therapeutic strategy. ACS Comb Sci 22, 297-305 https://doi.org/10.1021/acscombsci.0c00058
- Geretti AM and Easterbrook P (2001) Antiretroviral resistance in clinical practice. Int J STD AIDS 12, 145-153 https://doi.org/10.1258/0956462011916938
- Vandyck K and Deval J (2021) Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 49, 36-40 https://doi.org/10.1016/j.coviro.2021.04.006
- Nashed NT, Aniana A, Ghirlando R, Chiliveri SC and Louis JM (2022) Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor. Commun Biol 5, 160
- Tzou PL, Tao K, Pond SLK and Shafer RW (2022) Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS One 17, e0261045